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Abstract Wildebeest-associated malignant catarrhal
fever (WA-MCF), an acute lymphoproliferative disease of
cattle caused by alcelaphine herpesvirus 1 (AlHV-1),
remains a significant constraint to cattle production in
nomadic pastoralist systems in eastern and southern Africa.
The transmission of WA-MCF is dependent on the pres-
ence of the wildlife reservoir, i.e. wildebeest, belonging to
the species Connochaetes taurinus and Connochaetes
gnou; hence, the distribution of WA-MCF is largely
restricted to Kenya, Tanzania and the Republic of South
Africa, where wildebeest are present. WA-MCF is analo-
gous to sheep-associated MCF (SA-MCF) in many aspects,
with the latter having sheep as its reservoir host and a more
global distribution, mainly in developed countries with
intensive livestock production systems. However, unlike
SA-MCF, the geographic seclusion of WA-MCF may have
contributed to an apparent neglect in research efforts aimed
at increased biological understanding and control of the
disease. This review aims to highlight the importance of
WA-MCF and the need for intensified research towards
measures for its integrated control. We discuss current
knowledge on transmission and geographical distribution
in eastern and southern Africa and the burden of WA-MCF
in affected vulnerable pastoral communities in Africa.
Recent findings towards vaccine development and perti-
nent knowledge gaps for future research efforts on WA-
MCF are also considered. Finally, integrated control of
WA-MCF based on a logical three-pronged framework is
proposed, contextualizing vaccine development, next-gen-
eration diagnostics, and diversity studies targeted to the
viral pathogen and cattle hosts.
Introduction
Malignant catarrhal fever (MCF), also referred to as
African malignant catarrhal fever, bovine malignant
catarrhal fever, or Snotsieke is a collective term for the
clinicopathological signs manifested by cattle and other
susceptible ungulates when infected with viruses of the
genus Macavirus of the subfamily Gammaherpesvirinae
[1]. Two viruses are important with respect to MCF in
cattle; alcelaphine herpesvirus 1 (AlHV-1) and ovine
herpesvirus 2 (OvHV-2). The natural hosts for AlHV-1
are blue and black wildebeest (Connochaetes taurinus
and Connochaetes gnou, respectively). Sheep (Ovies
aries), on the other hand, are the natural hosts for
OvHV-2. Cattle are susceptible to both AlHV-1 and
OvHV-2. Infection of cattle with AlHV-1 results in
wildebeest-associated MCF (WA-MCF), while OvHV-2
causes sheep-associated MCF (SA-MCF). Each virus is
adapted to its natural host, therefore causing inapparent
infection in that species. WA-MCF in cattle mainly
occurs in Kenya, Tanzania and South Africa and is
restricted to specific geographical zones and private
conservancies where the susceptible cattle interact with
wildebeest, which are asymptomatic carriers of AlHV-1.
Unless otherwise stated, this review focuses on WA-
MCF in eastern and southern Africa.
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Etiology of WA-MCF
The history of WA-MCF arguably dates back as far as the
co-existence of cattle, wildebeest and other natural hosts.
However, the earliest and most comprehensive report of
WA-MCF in sub-Saharan Africa was that by Plowright and
colleagues [2], which described AlHV-1 as the etiological
agent of WA-MCF and the blue wildebeest as the natural
host for the virus in East Africa. Previous studies on the
natural hosts indicate that almost 100 % of wildebeest are
asymptomatic carriers of AlHV-1 [3]. In wildebeest,
newborn calves may acquire AlHV-1 infection either pre-
natally through congenital transmission in utero from
infected dams [4] or perinatally by interaction with other
infected calves shedding high titers of the cell-free virus in
their ocular and nasal secretions [5]. The infected calves
subsequently acquire neutralizing antibodies to the virus
and remain latently infected throughout their lives [6]. As
with other herpesviruses, AlHV-1 may be reactivated in
adult wildebeest if their immunological competence is
compromised by pregnancy or by stressful conditions such
as captivity or starvation, thereby rendering them infective
to cattle and other susceptible hosts [7].
Transmission of AlHV-1 to cattle occurs when they
come into close contact with wildebeest calves shedding
cell-free viruses in their ocular and nasal secretions [8].
The respiratory tract is the natural route of infection. There
is no documented evidence of horizontal transfer of AlHV-
1 from infected cattle to uninfected cattle, and hence,
infected cattle are terminal/dead-end hosts of AlHV-1.
However, vertical transmission of the virus also occurs in
cattle, as in wildebeest, where the infected cow transmits
the virus transplacentally to her unborn foetus in the course
of gestation [9].
Contact of cattle with fetuses and placental material of
calving wildebeest has been advanced as another possible
mode of transmission of AlHV-1 [10]. This mode of
transmission was based on the demonstration of cell-free
virus in unborn fetuses and placental tissue of calving
wildebeest. Although previous studies by Rositter and co-
workers [11] indicated that the virus was not present in
fetal tissue and fluids, Lankester et al. [5] demonstrated the
presence of AlHV-1 viral DNA in 50 % of placentae of
calving wildebeest in Tanzania. Therefore, transmission of
AlHV-1 from calving wildebeest to cattle through contact
with fetal and placental material may be a possible mode of
infection, and the physical presence of these tissues in
rangelands should be viewed as visual indicators of new-
born wildebeest calves, representing a real threat of
infection to cattle.
The involvement of a vector or intermediate host in the
transmission of AlHV-1 from wildebeest to cattle remains
largely speculative. Barnard and co-workers [12] observed
transmission of AlHV-1 in northwestern Transvaal (pre-
sently Northwest Province), South Africa. In that study, the
incidence of WA-MCF in cattle was negatively correlated
with the proximity to wildebeest, and the number of cases
in cattle peaked in the spring season, during which
wildebeest calves under the age of 3 months were absent.
Since young calves (\ 3 months) are implicated in active
transmission of AlHV-1, their absence was suggestive of
possible involvement of an intermediate host or vector in
the transmission cycle of WA-MCF to cattle. Subsequent
investigations, however, failed to find evidence that
arthropod vectors are involved in the spread of the virus
[13]. Hence, to date, there remains no substantive evidence
of an intermediate vertebrate or invertebrate host in the
transmission of AlHV-1 from wildebeest to cattle.
As with other herpesviruses, the exact incubation period
of AlHV-1 in cattle and other experimental hosts is
uncertain. Mushi et al. [14] reported a mean incubation
period of 14 days in rabbits infected with AlHV-1, while
Jacoby et al. [15] reported 21–90 days in rodent models of
AlHV-1. In cattle, a mean incubation period of 16–29 days
was achieved in an experimental infection with AlHV-1
[16], while in a more recent experimental investigation, the
observed incubation period ranged between 21 and 68 days
[17]. Based on these reports, the incubation period of
AlHV-1 in susceptible hosts is arguably a function of the
virus titer upon infection, host immunity, the route of
inoculation, or other factors. However, 95 %–100 % of
affected cattle die within 4–7 days of the onset of clinical
signs. Recovery of cattle from natural infection of WA-
MCF is not fully understood or substantially documented,
although there are existing reports of recovery from
experimental infection [9].
The WA-MCF landscape in eastern and southern
Africa
At present, WA-MCF remains a serious cause of human-
wildlife conflict between pastoralists and wildlife custodi-
ans in the vast rangelands of sub-Saharan Africa. The
disease is largely restricted to wildebeest zones: com-
monly, open savannah grasslands, which are home to large
populations of wildebeest, other wild ungulates and live-
stock. Cattle and wildebeest are herbivores, exhibiting over
70 % overlap in nutritional requirements and dietary
preferences [18], which favors close inter-species interac-
tions, facilitating transmission of WA-MCF. Peak trans-
mission of WA-MCF occurs during the highly
synchronized, annual wildebeest calving season. This sea-
son is characterized by migration of large herds of
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wildebeest to their preferred calving zones in the savannah
plains, where they encounter cattle grazing in the lush
pastures of the plains. The calving sites inevitably become
hotspots for WA-MCF transmission.
Epidemiology of WA-MCF in eastern Africa
In eastern Africa, WA-MCF is commonly referred to by
pastoralists as ‘‘ugonjwa wa nyumbu’’ a Swahili term
directly translated to mean ‘‘disease of the gnu or wilde-
beest.’’ It is the most important cattle disease with the
highest perceived impact on cattle production and liveli-
hoods of pastoralist communities [19]. The principal
reservoirs of WA-MCF in East Africa are the blue wilde-
beest, Connochaetes taurinus. Annual outbreaks of WA-
MCF occur in the wildebeest zones in Kenya and Tanzania,
coinciding with the wildebeest calving season. Peak
transmission is reported between February and April in
Tanzania, varying slightly to March and June in Kenya,
every year [20]. Figure 1 summarizes WA-MCF hotspots
in eastern Africa.
In Kenya, the WA-MCF landscape can be mapped onto
three principal wildebeest zones, located in the south-
western region of the country. They include i) the Maasai
Mara ecosystem, comprising of the Maasai Mara National
Reserve, associated private group ranches, and surrounding
areas of Narok county stretching into Serengeti in Tanza-
nia; ii) the Athi-Kaputiei ecosystem comprising of the
Nairobi National Park, Kitengela Game Conservation Area,
and Athi-Kaputiei plains, currently located in the larger
administrative areas of Kajiado and Machakos counties;
and iii) the Amboseli-Kilimanjaro ecosystem, comprising
the Amboseli National Park and associated group ranches,
stretching into Mt. Kilimanjaro in Tanzania [21–23].
In Tanzania, the WA-MCF landscape is found in the
northern region of the country and can be mapped onto four
principal zones: i) the Serengeti ecosystem contiguous with
the Maasai Mara ecosystem in southern Kenya, encom-
passing the Serengeti National Park, Maswa Game Reserve
and the Serengeti plains; ii) the Ngorongoro conservation
area, extending to Loliondo, a known wildebeest calving
area, and the Angata Kheri and Salei plains, the latter of
which are documented as a recent extension of the wilde-
beest zone in Ngorongoro due to an increase in migratory
populations of wildebeest [20]; iii) the Manyara-Lake
Natron ecosystem, mainly the northern plains stretching
north of Tarangire National Park (TNP), through Manyara
ranch to the shores of Lake Natron; and finally, iv) the
Tarangire-Simanjiro ecosystem in the Maasai Steppe,
including Tarangire National Park and stretching eastward
to the Simanjiro plains, a dispersal and calving area for
wildebeest and other wildlife species.
Epidemiology of WA-MCF in southern Africa
In southern Africa, WA-MCF occurs in the Republic of
South Africa, Namibia, Zimbabwe, Zambia and Botswana,
with significant impact mainly on commercial cattle pro-
duction systems and, to a lesser extent, smallholder sys-
tems. Although WA-MCF is widely documented in South
Africa, it is equally of significant importance in Namibia,
Zambia, Zimbabwe and Botswana, where there are sub-
stantial populations of wildebeest [24]. A recent outbreak
in Zimbabwe, where WA-MCF accounted for 71 % and
21 % losses of cattle reared under commercial and small-
holder production systems respectively, demonstrated the
importance of the disease in the southern Africa region
[25].
The epidemiology of WA-MCF in southern Africa tends
to differ from that in eastern Africa, where, two annual
outbreaks are observed [25, 26]. The first outbreak occurs
early in the year as calving season of the wildebeest starts
in December. WA-MCF cases begin to be reported in
January and peak in March and April, as in Tanzania and
Kenya. However, a second annual outbreak, where the
majority of the cases are observed, occurs in the months of
September to November when wildebeest calves are
8-10 months old. This outbreak is hypothesized to be
attributed to stress in cattle caused by unusually cold rainy
weather during the winter months, coupled with poor
grazing conditions [27].
In South Africa, cases of WA-MCF have been reported
with increasing frequency as a result of growth in game
ranching, wildlife and the tourism industry [27]. The
majority of cases occur in Limpopo and Northwest pro-
vinces, where the number of game ranches have increased.
Substantial losses have been reported in the Northwest
Province, with incidences as high as 34 % in farms adja-
cent to game reserves. Black wildebeest (Connochaetes
gnou) play an important role in the epidemiology of WA-
MCF in South Africa, unlike in eastern Africa, where blue
wildebeest (Connochaetes taurinus) are regarded as the
principal natural hosts [3]. A comparison of outbreaks
associated with black wildebeest in South Africa between
the periods 1981–1983 and 1988–1990 revealed that the
number of cases of WA-MCF where only black wildebeest
were involved had increased 7-fold [28] due to growth in
the number of farms on which black wildebeest were kept.
Annual incidence of WA-MCF is highly variable. In
Kenya, 1 %-21 % annual incidence was estimated by
Ngotho and co-workers [29], whereas Bedelian et al. [19]
estimated the incidence to be 3 %-12 % in the year
2003-2004. In Tanzania’s Ngorongoro area, the mean
incidence for the year 2000 was estimated at 5.6–6.2 %
[20]. Higher annual incidence of WA-MCF has been
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reported in South Africa, rising up to 34 % due to an
increase in game farming and ecotourism [26, 30]. An
upward trend in the number of outbreaks has been noted in
recent years, with up to 50 outbreaks of WA-MCF being
reported per annum in sub-Saharan Africa [31, 32].
The true incidence of WA-MCF is higher than current
estimations due to widespread underreporting and misdi-
agnoses. Nevertheless, several factors may account for the
high variation in reported annual incidence of WA-MCF in
sub-Saharan Africa. Annual rainfall levels, proximity of
cattle populations to wildebeest calving areas, density of
wildebeest in the area and host genetics may account for
the observed variation in annual incidence of WA-MCF.
The highest incidence of the disease occurs in the cattle
populations with the nearest proximity to the wildebeest
calving areas and is positively correlated with density of
wildebeest interacting with cattle populations [19]. WA-
MCF incidence is also associated with decreased annual
rainfall, decrease in browser vegetation and drought, as
these adverse conditions discourage the movement of
wildebeest to their usual calving zones, thereby reducing
transmission of WA-MCF [33]. The increase in human
populations, coupled with agricultural intensification, has
resulted in invasion and human settlement in rangelands
Fig. 1 WA-MCF landscape in
eastern Africa: maps indicating
the transmission hotspots of
WA-MCF in Kenya and
Tanzania
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originally reserved for wildlife. Encroachment on wilde-
beest zones and migratory routes has been noted [34].
These trends may translate to an expansion, rather than a
contraction, of the WA-MCF landscape in sub-Saharan
Africa, as the present realities of climate change, indus-
trialization and increased pressure on existing land
resources portend an inevitable increase in human-wildlife-
livestock conflict for the limited pastures, providing ideal
conditions for WA-MCF transmission.
Contextualizing the burden of WA-MCF
in affected countries
The case fatality rate of WA-MCF in affected cattle is
95-100 %. This annual catastrophic loss of cattle through
WA-MCF compromises the livelihoods of affected noma-
dic pastoralist communities in eastern and southern Africa.
Significant losses of cattle by commercial farmers are a
major concern in southern Africa, where cattle are kept
under intensive commercial systems for beef production
[25, 30]. Furthermore, the localized mass loss of livestock
resources due to WA-MCF may pose significant population
bottlenecks and subsequent loss of valuable diversity. The
loss of livestock genetic resources is of particular concern
in Africa, where there is marked geographical segregation
of locally adapted cattle breeds, whose genetic conserva-
tion is critical [35].
To date, there is no effective treatment or vaccine for
WA-MCF, and field surveillance in the hotspot areas
remains poor. Avoidance of interaction between wildebeest
carriers and cattle remains the only control strategy for
WA-MCF in the affected countries [20]. Although WA-
MCF is not classified by the World Organization for Ani-
mal Health (OIE) as a transboundary or notifiable disease
(2015), the disease is of significant national importance in
Kenya, Tanzania, South Africa, Namibia, Zimbabwe,
Botswana and Zambia, especially in areas where cattle
share grazing sites with wildebeest. The disease has direct
impact not only on commercial farmers but also small-
holder farmers whose economic livelihoods and sociocul-
tural lives are affected by the death of their cattle, resulting
in loss of income from sale of milk and beef [19, 25].
Limited options are available for mitigation of the
damage caused by WA-MCF. Cattle owners adopt either
disposal or avoidance as a strategy. If infection has
occurred, the pastoralists are forced to dispose off the
symptomatic cattle quickly for slaughter at a throwaway
price, usually 30 % or less of that of healthy cattle [19, 20].
As a preventive strategy, pastoralists avoid grazing their
animals in wildebeest zones during the calving seasons and
instead find pastures in thickets and highlands. Avoidance
is a costly strategy, because, although the cattle are
protected from WA-MCF, they are exposed to tsetse flies
and ticks, further predisposing the cattle to deadly vector-
borne diseases, mainly trypanosomosis and east coast
fever, which may cause death, loss of productivity, and
demand for costly veterinary care [19]. In eastern Africa,
mobility of cattle from wildebeest zones over long dis-
tances, sometimes over 60 km, affects their body condition
and productivity, reducing milk yield by up to 64 %, fur-
ther increasing the economic vulnerability of pastoralist
communities [36].
WA-MCF also threatens the conservation of wildebeest
zones in the affected countries. It remains a hindrance in
fostering community-led efforts for sustainable conserva-
tion of the dwindling wildebeest populations, since their
mere existence is equated by livestock farmers to death of
cattle [34]. Yet, in countries such as Kenya and Tanzania,
wildebeest are keystone wildlife species, and their spec-
tacular annual migration across the Maasai Mara-Serengeti
corridor, often termed the ‘‘8th wonder of the world,’’ is a
global tourism attraction generating millions of foreign
income to the countries. WA-MCF threatens establishment
of community conservancies in wildebeest dispersal areas
and migratory corridors and curtails growth of an eco-
tourism industry that has the potential to support vulnerable
communities through payment of ecosystems services and
other incentives [37].
Integrated control of WA-MCF: current
knowledge and perspectives for future research
The control of WA-MCF to date remains largely incidental,
and numerous knowledge gaps on the disease exist, which
demand concerted research efforts to be addressed and a
strategy for integrated control. In view of the current
knowledge and with reference to steps taken to control
other infectious diseases, we have proposed a three-pron-
ged framework for the integrated control WA-MCF,
encompassing vaccine development, efficient diagnostics
and genetic studies of WA-MCF, as summarized in Fig-
ure 2 and discussed in detail in the sections below.
Next-generation diagnostics for WA-MCF
MCF viruses are not readily or rapidly diagnosed by con-
ventional virus isolation procedures. Confirmative diag-
nosis of WA-MCF relies mainly on postmortem
histopathological analysis of samples from dead cattle, as
this is the definitive test recommended by the OIE [38].
Serological tests for detection of MCF antibodies have
been developed, including a competitive inhibition ELISA
(CI-ELISA) [39] and a direct ELISA assay [40]. Never-
theless, their utility in routine diagnosis of WA-MCF cases
Wildebeest-associated malignant catarrhal fever 5
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is limited by the rapid and high case fatality rates associ-
ated with AlHV-1 infection, because most cattle die before
a detectable antibody response has been raised [20]. These
serological tests also exhibit considerable cross-reactivity
with other macaviruses and must be used with caution, as
they may not differentiate between AlHV-1 and OvHV-2
infections. Several PCR-based assays for detection of
AlHV-1 DNA have also been developed over the years, as
reviewed extensively by Li et al. [41]. DNA-based assays
can distinguish between AlHV-1 and other macaviruses
and have higher sensitivity than the ELISA assays. How-
ever, the current repertoire of diagnostic approaches for
WA-MCF require elaborate protocols to be performed by
trained personnel using specialized equipment, such as
PCR machines, ELISA readers and microscopy apparatus.
Samples from suspected cases must therefore be shipped
from the field to the veterinary laboratories where the
required facilities can be availed for molecular, serological
and microscopy tests. This process is lengthy and costly
and undoubtedly delays diagnosis and intervention during
WA-MCF outbreaks.
It is worth noting that the current repertoire of diag-
nostic approaches do not support active field surveillance
of WA-MCF in hotspot areas within the region. A robust
surveillance system is highly dependent on development of
diagnostic solutions for sensitive and speedy detection of
the causative pathogen under field conditions, given that up
to 100 % of symptomatic animals die within two weeks
[20]. The lack of simple and low-cost diagnostic tests for
AlHV-1 has arguably contributed to underreporting of
WA-MCF cases in rural areas and may also be associated
with the high variability in the annual incidence rates
recorded for WA-MCF in sub-Saharan Africa. There is an
urgent need to bridge this gap by developing low-cost
penside diagnostic assays for rapid detection of WA-MCF.
These tests should, however, allow differential diagnosis of
AlHV-1 from other macaviruses and infectious diseases
that exhibit clinical signs similar to those of WA-MCF,
such as bluetongue, bovine mucosal disease and infectious
bovine rhinotracheitis [42]. This next generation of diag-
nostic tests should exhibit high sensitivity, specificity,
speed and ease of use. The development, deployment and
adoption of such assays would significantly strengthen
national surveillance systems for WA-MCF in affected
countries in sub-Saharan Africa.
Vaccine development for WA-MCF
Effective control of WA-MCF relies greatly on develop-
ment of an effective vaccine to block the transmission of
AlHV-1 from wildebeest to cattle. Such a vaccine would be
highly desirable, as it would negate the need to separate
cattle and other susceptible ungulates from wildebeest
reservoirs. A successful vaccine for WA-MCF would
therefore assure pastoralists of quality nutrition for their
cattle all year round and alleviate the risk of acquiring
vector-borne diseases, thereby optimizing milk and meat
productivity and guaranteeing the economic livelihoods of
both smallholder and commercial cattle farmers [36]. In the
wider context, the availability of a WA-MCF vaccine
would contribute to the conservation of the rich genetic
resource of locally adapted indigenous cattle breeds present
in eastern and southern Africa through protection of the
animals against WA-MCF, vector-borne diseases and
starvation. Hence, intensified research and efforts towards
an effective WA-MCF vaccine is justified.
Concerted efforts to develop an effective vaccine for
WA-MCF have been made over the years. Table 1 pro-
vides a summary of some of the key research efforts that
have been made in vaccine development for WA-MCF
over the last six decades. However, these efforts have so far
not translated to a commercial vaccine for use by pas-
toralists. Initial attempts to develop a WA-MCF vaccine
did not provide substantial protection against natural
infection with virulent AlHV-1 [43–45]. In one study, the
potential of inactivated virus as a vaccine was tested, but
this failed to protect cattle from challenge with natural
infection [46]. In another trial, vaccination of local animals
with homologous virus isolated from cattle in America,
failed to provide adequate protection against challenge
despite repeated inoculations [47].
The potential of virus preparations attenuated for viru-
lence through serial passaging or deletion of virulent genes
has been the focus of WA-MCF vaccine studies in the
recent past. The performance of a live attenuated vaccine
based on a high-pass attenuated C500 strain of AlHV-1 was
Fig. 2 Proposed 3-pronged framework for integrated control of WA-
MCF in eastern and southern Africa. Contextualizing vaccine
development, next-generation diagnostic technologies and virus and
host diversity in a multi-dimensional strategy for surveillance and
control of WA-MCF
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assessed in cattle [17]. The attenuated vaccine, adminis-
tered with Freund’s adjuvant intramuscularly, provided
protective immunity against intranasal challenge with vir-
ulent AlHV-1. In a follow-up investigation, the attenuated
vaccine gave a 6-month protection window when com-
bined with Emulsigen, a licensed adjuvant, and adminis-
tered to cattle by intramuscular inoculation [48, 49].
Another study by Palmeira and co-workers [50] demon-
strated the application of recombinant AlHV-1 ORF73 null
mutants, which lacked expression of the latency-associated
nuclear antigen (LANA) homolog encoded by ORF73, as a
promising recombinant vaccine candidate. Although not
tested or validated in cattle, the ORF73 null mutant was
apathogenic in rabbit models of WA-MCF and triggered a
significant humoral response and protection from MCF-
related pathology in vaccinated rabbits, conferring protec-
tion against subsequent infection with a virulent strain of
AlHV-1.
The potential of these candidates as vaccines for WA-
MCF appears promising but requires validation in cattle
and other susceptible hosts. Presently, there is a paucity
of data from large-scale field vaccine trials in locally-
adapted cattle in eastern and southern Africa, which
would be useful in validating promising candidates.
Additionally, there remains a need for current vaccine
studies to incorporate or identify markers to differentiate
between infected and vaccinated animals (DIVA vaccine).
DIVA vaccines incorporate or omit one or more
detectable antigens, which then form the basis of distin-
guishing between natural challenge and vaccination by
use of a companion serological or molecular diagnostic
test. DIVA vaccines have been developed for a range of
veterinary diseases affecting cattle and other livestock, as
reviewed previously [51, 52]. Embracing a DIVA strategy
for WA-MCF vaccine development would be useful in
assessing the effectiveness of vaccination programmes,
monitoring vaccine coverage and verifying breakthrough
epidemics. The use of companion diagnostic tests along-
side a DIVA vaccine would ensure compatibility between
surveillance and vaccination programmes in working
towards a comprehensive integrated control strategy for
WA-MCF.
Table 1 Vaccine development timeline: summary of some of the key research efforts in vaccine development for WA-MCF over the last six
decades, indicating the vaccine formulation, experimental hosts and outcomes
Vaccine formulation Host tested Year [Ref] Outcome
Inactivated AlHV-1 virus Rabbit and Cattle 1954 [43] Induced neutralizing antibodies in the serum
Inactivated cell cultures of AlHV-1 (WC11
strain) in Freund’s incomplete adjuvant
Cattle 1975 [46] High levels of neutralizing antibodies induced.
No protective immunity to parenteral or natural
challenge with virulent virus
Inactivated cell-free AlHV-1 virus in
Freund’s complete adjuvant
Rabbit 1980 [44] High levels of neutralizing antibodies induced.
Vaccinated animals protected against
parenteral challenges with cell-free virus, but
succumb and die on challenge with cell-
associated virus (infected lymph nodes)
Inactivated AlHV-1 strain C500 Rabbit 1980 [45] Inactivated cell-free virulent AlHV-1 C500
AlHV-1-like virus (707K virus) preparation
isolated from clinical cases in American
cattle
Cattle 1991 [47] No protective immunity achieved with single or
multiple rounds of vaccine administration.
Cattle exposed to repeated inoculations
developed MCF-like symptoms
Attenuated C500 strain-AlHV-1 from
serially passaged cell cultures with
Freund’s (unlicensed) adjuvant
Cattle 2008 [17] Oro-nasal mucosal immunity induced in
vaccinated cattle with high titres virus-
neutralizing antibodies
Attenuated C500 strain-AlHV-1 from
serially passaged cell cultures with
Emulsigen (licensed) adjuvant
Cattle 2012 [48] High titres of virus-neutralizing antibodies in
both plasma and nasal secretions of vaccinated
cattle. 6-month duration of protective
immunity in vaccinated animals
Recombinant AlHV-1 virus with ORF73
deletion
Rabbit 2013 [50] ORF73-deleted recombinant virus induced a
strong antibody response. Animals protected
against MCF-associated pathology following
lethal challenge and with virulent virus
Attenuated C500 strain-AlHV-1 from
serially passaged cell cultures with
Emulsigen (licensed) adjuvant and
unmethylated CpG oligodeoxy nucleotide
(TLR9 agonist)
Cattle 2014 [49] Unmethylated CpG oligodeoxynucleotide offers
no additional advantage to length or level of
protective immunity achieved using attenuated
AlHV-1 with Emulsigen (licensed) adjuvant
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The role of virus and host diversity in WA-MCF
The genome of AlHV-1, the causative agent of WA-MCF,
was sequenced in 1997 [53]. Despite the availability of
genome information for AlHV-1 and those of closely
related MCF viruses [54, 55], genetic variation and evo-
lution of AlHV-1 in wild and domestic hosts is poorly
understood, as minimal attempts have been made to
investigate viral diversity in clinical cases or in field iso-
lates. However, a previous study by Shih and co-workers
[56] outlined the existence of genetic variation in MCF
viruses from different hosts based on restriction enzyme
digestion patterns. In a recent study, the viral lytic trans-
activator protein gene (ORF50), the main diagnostic target
in the nested PCR assay for AlHV-1, was well conserved
among field samples in Tanzania, whereas a novel viral
glycoprotein (A9.5) was found to be highly polymorphic at
both the nucleotide and the protein level [5]. These
observations indicate the need to investigate virus diversity
in WA-MCF cases, because, while it is generally accepted
that DNA viruses such as AlHV-1 may exhibit lower rates
of mutation and genetic variation compared to RNA viru-
ses, DNA viruses can accumulate point mutations and
length polymorphisms, which may influence genetic vari-
ability, genome regulation and functions of key viral genes
such as those responsible for virulence [57].
At present, it remains unknown if AlHV-1 is segregated
into single or multiple genetic subtypes and whether there
are any observable geographical patterns of distribution in
eastern and southern Africa. The availability of powerful
sequencing technologies presents fresh opportunities for
genetic characterization of this important cattle pathogen.
These technologies may be employed for spatial and tem-
poral characterization of virus isolates from different out-
breaks, geographical areas and hosts to provide insights
into the genetic variability and evolution of the virus. This
knowledge is crucial in vaccine trials and in guiding the
design of diagnostic tests to diagnose all or at least the
majority of the possible genetic variants.
The role of host genetics and immunity in WA-MCF has
not been studied. A rich genetic diversity of locally adapted
indigenous cattle exists in eastern and southern Africa
where WA-MCF is present [58]. However, whether the
genetic background of the cattle affects susceptibility or
tolerance to AlHV-1 or plays a role in disease progression
and pathology remains an area for future research. Previous
studies of infections with related gammaherpesviruses have
demonstrated a role for the host genotype in influencing
immune responses during the course of infection [59].
There exists a need to understand both viral and host
diversity and their interactions in immunological contain-
ment and pathology of WA-MCF. It will therefore be
important to incorporate this knowledge in the design of
diagnostic assays and in a rational WA-MCF vaccine
development strategy.
Conclusions
The control of WA-MCF in sub-Saharan Africa will be
dependent on adoption of a comprehensive logical framework
for integrated control as proposed in this review, rather than the
present strategy of avoidance. While progress has been made
over the decades towards understanding the etiology and
pathology of this disease and development of a vaccine, there
are persistent knowledge gaps concerning the role of virus and
host diversity in clinical disease as well as opportunities for
research on field-friendly diagnostic technologies. There is a
need to harmonize resources towards research and a rational
multi-dimensional strategy for integrated control, applicable to
the regional context, without whichWA-MCFwill continue to
be a threat not only to cattle production but also to wildlife
conservation in eastern and southern Africa.
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